Kansızlık ve Saç Dökülmesi

Ferrum (demir) eksikliği bayan saç dökülmelerinde en çok teşhis edilen dökülme sebeplerindendir. Demir eksikliğinin kansızlığa ve bu yolla saç dökülmesine sebep olabileceği yönünde bir çok bilimsel çalışma yapılmıştır. Demir ilacı verilerek kansızlığın tedavisi yapıldığında saç dökülmeside durmaktadır. Demir eksikliğinin bir diğer sonucu ise menopoza girmiş kadınlardaki saç kalite kaybıdır, çalışmaların biri bu konudadır.

Bilimsel yayın 1

Leonid Benjamin Trost MD, Wilma Fowler Bergfeld MD, Ellen Calogeras, RD, LD, MPH The diagnosis and treatment of iron deficiency and its potential relationship to hair loss

Journal of the American Academy of Dermatology Volume 54, Issue 5 , Pages 824-844, May 2006

Iron deficiency is the world’s most common nutritional deficiency and is associated with developmental delay, impaired behavior, diminished intellectual performance, and decreased resistance to infection. In premenopausal women, the most common causes of iron deficiency anemia are menstrual blood loss and pregnancy. In men and postmenopausal women, the most common causes of iron deficiency anemia are gastrointestinal blood loss and malabsorption. Hemoglobin concentration can be used to screen for iron deficiency, whereas serum ferritin concentration can be used to confirm iron deficiency. However, the serum ferritin concentration may be elevated in patients with infectious, inflammatory, and neoplastic conditions. Other tests may be needed, such as erythrocyte zinc protoporphyrin concentration, transferrin concentration, serum iron concentration, and transferrin saturation. The cause of iron deficiency must be identified. If the patient is male, postmenopausal female, or has risk factors for blood loss, then the patient should be evaluated for sources of blood loss, especially gastrointestinal (eg, colon cancer). Several studies have examined the relationship between iron deficiency and hair loss. Almost all have addressed women exclusively and have focused on noncicatricial hair loss. Some suggest that iron deficiency may be related to alopecia areata, androgenetic alopecia, telogen effluvium, and diffuse hair loss, while others do not. Currently, there is insufficient evidence to recommend universal screening for iron deficiency in patients with hair loss. In addition, there is insufficient evidence to recommend giving iron supplementation therapy to patients with hair loss and iron deficiency in the absence of iron deficiency anemia. The decision to do either should be based on clinical judgment. It is our practice at the Cleveland Clinic Foundation to screen male and female patients with both cicatricial and noncicatricial hair loss for iron deficiency. Although this practice is not evidence based per se, we believe that treatment for hair loss is enhanced when iron deficiency, with or without anemia, is treated. Iron deficiency anemia should be treated. Treating iron deficiency without anemia is controversial. Treatment of nutritional iron deficiency anemia includes adequate dietary intake and oral iron supplementation. Excessive iron supplementation can cause iron overload and should be avoided, especially in high-risk patients such as those with hereditary hemochromatosis. Patients who do not respond to iron replacement therapy should undergo additional testing to identify other underlying causes of iron deficiency anemia.

Bilimsel yayın 2

Low iron stores: a risk factor for excessive hair loss in non-menopausal women

European Journal of Dermatology. Volume 17, Number 6, 507-12, November-December 2007, Investigative report

DOI : 10.1684/ejd.2007.0265


Author(s) : Claire Deloche, Philippe Bastien, Stéphanie Chadoutaud, Pilar Galan, Sandrine Bertrais, Serge Hercberg, Olivier de Lacharrière , L’Oréal Recherche, Clichy, FranceFax: (+33)1 47 56 82 21, U557 Inserm (UMR INSERM/INRA/CNAM), 5 rue du Vertbois, Paris, 75003 France.

Summary : Iron deficiency has been suspected to represent one of the possible causes of excessive hair loss in women. The aim of our study was to assess this relationship in a very large population of 5110 women aged between 35 and 60 years. Hair loss was evaluated using a standardized questionnaire sent to all volunteers. The iron status was assessed by a serum ferritin assay carried out in each volunteer. Multivariate analysis allowed us to identify three categories: “absence of hair loss” (43%), “moderate hair loss” (48%) and “excessive hair loss” (9%). Among the women affected by excessive hair loss, a larger proportion of women (59%) had low iron stores (<; 40 µg/L) compared to the remainder of the population (48%). Analysis of variance and logistic regression show that a low iron store represents a risk factor for hair loss in non-menopausal women.

Keywords : hair loss, non-menopausal women, serum ferritin



Auteur(s) : Claire Deloche1, Philippe Bastien1, Stéphanie Chadoutaud1, Pilar Galan2, Sandrine Bertrais2, Serge Hercberg2, Olivier de Lacharrière1

1L’Oréal Recherche, Clichy, FranceFax: (+33)1 47 56 82 21

2U557 Inserm (UMR INSERM/INRA/CNAM), 5 rue du Vertbois, Paris, 75003 France

accepté le 6 Juin 2007

Hair loss in women is a common trait and the prevalence is age dependent [1]. When a woman consults a dermatologist about hair loss, her condition may or may not lead to alopecia, defined as a decrease in hair density. Patterned androgenic alopecia occurs in 37% of post-menopausal women [2] but only in 10-13% of non-menopausal women [2, 3]. Another hair trouble in non-menopausal women is increased hair loss or hair shedding, also known as chronic telogen effluvium (CTE) [3], affecting around 30% of women in the USA, UK and Japan [4]. Both diffuse androgen-dependent alopecia and chronic telogen effluvium are a major concern in dermatology [5]. However, it is important to remember that in clinical practice, women’s complaint of hair loss is still unclear or controversial [6, 7]; other causes must be taken into consideration.Iron deficiency has been suspected to represent one of the possible causes of excessive hair loss in women. Iron deficiency has been reported to be associated with chronic diffuse hair loss [5, 6, 8, 9]. A total iron depletion was observed when the serum ferritin was below 15 µg/L, and low iron stores with serum ferritin was between 15 and 30 µg/L [10]; Rushton [11] reported that the critical threshold of serum ferritin was 40 µg/L, a level under which increased telogen hair shedding was observed. So far, a direct relationship between ferritin levels and hair loss has not been confirmed by other studies [12, 13] and is still a matter of debate [14-16]. Some evidence was provided in a recent report [17] that decreased serum ferritin is associated with hair loss or alopecia in women; however, several parameters in this study, such as sample sizes, the ferritin thresholds and the clinical features [16, 17] need further explanation.To further investigate the relationship between iron store and hair loss, we decided to explore this relationship by assessing hair loss and measuring serum ferritin concentration, which is closely related to iron stores [10], in a very large sample of subjects by taking the advantage of the SU.VI.MAX epidemiological study, which provided us with the opportunity to study, for the first time, a large cohort of 5110 women. The aim of the study was to evaluate a possible link between iron stores based on the assessed ferritin level, and hair loss in women.

Materials and methods


5110 women aged between 35 and 60 years were involved in the study. This cohort of volunteers was part of the SU.VI.MAX trial, a large French epidemiological study [18, 19] approved by the ethical Committee of Paris-Cochin. SU.VI.MAX, which stood for “SUpplementation en VItamines et Minéraux AntioXydants”, was a randomized double blind, placebo-controlled, primary-prevention trial designed to test the efficiency of daily supplementation with anti-oxidant, vitamins and minerals at nutritional doses, in reducing the incidence of cancers and ischemic vascular diseases in a middle-age general population. Detailed description of the SU.VI.MAX study-design, randomization and participant characteristics have been previously reported [18, 19].

Hair loss assessment

Hair loss was assessed with the help of a set of descriptive questions extracted from a self-assessment questionnaire which had been sent to all volunteers at inclusion in the study (table 1). The quantification of hair loss was estimated by quantification of the hairs lost during washing, brushing, after drying with a towel, on the pillow after a night’s sleep and on clothes. Hairs that shed were quantified as none or a little, a few and a lot of hairs. Questions concerning the degree of self-perceived hair loss were also provided to establish if the volunteers consider themselves to be concerned by hair loss (non existent, normal, abnormal) and were included in the data analysis. Multiple correspondence analysis and hierarchical cluster analysis (HCA) [20] were used to group the answers with similar expression patterns. This allowed us to identify three distinct groups of volunteers characterized by “absence of hair loss”, “moderate hair loss” and “excessive hair loss” (table 2).

Table 1 Hair loss questionnaire

• Do you feel involved by hair loss? Yes □ No □

• • If you feel involved by hair loss, do you estimate that your hair loss corresponds to a transient hair loss?

• do you estimate that your hair loss corresponds to a persistent hair loss?

• Yes □

• Yes □

• No □

• No □

• Currently, during hair washing, how much do you estimate your hair loss? Many hairs □ Few hairs □ Very few or None □

• Currently, drying your hair with a bath towel, how much do you estimate your hair loss? Many hairs □ Few hairs □ Very few or None □

• Currently, during hair brushing, how much do you estimate your hair loss? Many hairs □ Few hairs □ Very few or None □

• Currently, after a night sleep, how much do you estimate your hair loss on the pillow? Many hairs □ Few hairs □ Very few or None □

• Currently, during a day how much do you estimate your hair loss on your clothes? Many hairs □ Few hairs □ Very few or None □

Table 2 Hair loss classification according to descriptive questions on hair loss signs and hierarchical cluster analysis

Cluster 1“Absence of Hair Loss” Cluster 2 “Moderate Hair Loss” Cluster 3 “Excessive Hair Loss

“not concerned by hair loss” “hair loss self-perceived as normal hair loss” “hair loss self-perceived as abnormal hair loss”

“no hair loss or a little during the washing” “lose a few hairs during the washing” “lose a lot of hairs during the washing”

“no hair loss or a little during hair brushing” “lose a few hairs during hair brushing” “lose a lot of hairs during hair brushing”

“no hair loss or a little on the bath towel” “lose a few hairs on the bath towel” “lose a lot of hairs on the bath towel”

“no hair loss or a little on the pillow” “lose a few or a lot of hairs:

“no hair loss or a little on the clothes” on the pillow”

“lose a few or a lot of hairs on the clothes”

Biochemical measurements

The iron status was assessed by measuring the serum ferritin level and haemoglobin levels in each volunteer. At entry in the study, a 35 mL venous blood sample was collected. After collection (Becton Dickinson tubes), haemoglobin was measured immediately (cyanmethemoglobin method) and kept at + 4 °C in the dark until centrifugation and preparation of the aliquots. Serum ferritin levels were measured using a nephelometric assay (BNII Berhing) [21].

Statistical analysis

Descriptive and inferential analyses were performed using SPSS 11.0, SPAD 5.1 and SAS 8.2 statistical softwares. The detection limit of the serum ferritin assay caused some departure from normality even for log-transformed data. Therefore analyses based on ranks have been preferred. Analysis of variance (ANOVA) of serum ferritin level based on ranks has been carried out independently in post-menopausal and non-menopausal women, taking into account the age factors, “hemoglobin” and “hair loss classes” (table 2). For non-menopausal women, the use of intra-uterine devices or contraceptives was also taken into consideration. Comparisons of mean ranked serum ferritin levels relative to the hair loss classes were carried out using the Tukey-Kramer procedure for pairwise comparisons [22]. The relationship between the hair loss classes and serum ferritin levels were fitted using generalized logits [23] controlled for age, haemoglobin, and contraceptives or intra-uterine devices. The “excessive hair loss” class was chosen as the reference class; the significance level was set up at 0.05.


Hair loss quantification

Based on the questionnaire, hierarchical cluster analysis (HCA) using Ward’s criteria clearly identified three well-defined classes of women [20]. The planar projection of individuals(figure 1) displays the three clusters on the first factorial plan. The clusters are stretched along the first component, corresponding to an intensity hair loss axis. The U-shape representation of the clusters is characteristic of a Guttman effect [20] which opposes the classes “absence of hair loss” and “excessive hair loss” classes to “moderate hair loss” class on the second factorial axis. The three classes were characterized using modalities over-expressed in respect to the whole population (table 2). The ellipsoids displays the classes “absence of hair loss”, “moderate hair loss”, and “excessive hair loss” which correspond to 43%, 48%, and 9% of the 5110 women, respectively. Each point on this figure corresponds to a particular profile and is sized proportionally to the frequency of the profile in the studied population.

Link between hair loss and serum ferritin levels

In non-menopausal women, 41.5%, 48.6% and 10% displayed absence, moderate and excessive hair loss, respectively (table 3A). Among them, 23% (881/3759) presented iron depleted stores (serum ferritin levels < 15 µg/L). In addition, 57% [(881+1269)/3759] of non-menopausal women presented low iron stores (serum ferritin < 40 µg/L) (table 3A, figure 2).

In post-menopausal women, the iron loss caused by bleeding during menstruation does not occur anymore. Among them, 47.4%, 46% and 6.6% display absence, moderate and excessive hair loss respectively (table 3B). At that time, only 5% (67/1351) had depleted iron stores (serum ferritin < 15 µg/L) (table 3B). Similarly, the low iron stores (serum ferritin < 40 µg/L) affected only 23% [(67+243)/1351] of post-menopausal women versus 57% of non-menopausal women.

The detection limit of the serum ferritin assay caused some deviation from normality, even for log-transformed data. Since the parametric analyses could thus be biased, we decided to perform analyse based on ranks, The ANOVA based on ranks showed a significant effect of the mean serum ferritin level on hair loss (p = 0.01) only in non-menopausal women. The Tukey-Kramer test for pairwise comparisons showed significant differences between excessive hair loss and both absence (p = 0.01) and moderate (p = 0.02) hair loss (figure 3).

In non-menopausal women, with serum ferritin levels below 40 µg/L or below 15 µg/L, excessive hair loss was significantly more frequent (11.4% [(90+156)/(881+1269)] and 10.2%, respectively), compared to women with optimal levels of ferritin, above 70 µg/L (6.8%) (table 3A). Anemia (defined as hemoglobin < 120 g/L) concerned 10% [(173+43)/(881+1269)] and 19.6% of women presenting a serum ferritin level lower than 40 µg/L or 15 µg/L, respectively. With a serum ferritin level above 40 µg/L, only 1.8% [(23+7)/(937+672)] of the women showed anemia (table 4). Thus, a relationship between hair loss and anemia was noticed only when the body’s iron stores was below 40 µg/L.

Adjusted for age, haemoglobin, and the use of contraceptives or intra-uterine devices [21], generalized logits based on ranks for the absence versus excessive hair loss and moderate versus excessive hair loss were performed. A generalized logits model was preferred over a conventional polytomic logistic regression, since the assumption of proportional odds was rejected (score test for the proportional assumption, p = 0.009). The results showed that low serum ferritin levels appeared to be highly significantly linked to the presence of excessive hair loss in non-menopausal women (p = 0.005 for excessive hair loss versus absence of hair loss; p = 0.005 for excessive hair loss versus moderate hair loss). Model adequacy was supported by Hosmer and Lemeshow Goodness-of-Fit test [23]. In addition, the model based on the log transformed ferritin data (figure 4) shows similar results.

Table 3A Impact of iron store levels on hair loss status in non-menopausal women (n = 3759)

Ferritin (µg L-1) Hair loss Total

Absence of hair loss Moderate hair loss Excessive hair loss

< 15 Count 365 426 90 881

% within ferritin 41.4% 48.4% 10.2% 100.0%

[15-40] Count 512 601 156 1269

% within ferritin 40.3% 47.4% 12.3% 100.0%

[40-70] Count 385 469 83 937

% within ferritin 41.1% 50.1% 8.9% 100.0%

≥ 70 Count 297 329 46 672

% within ferritin 44.2% 49.0% 6.8% 100.0%

Total Count 1559 1825 375 3759

% within ferritin 41.5% 48.6% 10.0% 100.0%

Table 3B Impact of iron store levels on hair loss status in post-menopausal women (n = 1351)

Ferritin (µg L-1) Hair loss Total

Absence of hair loss Moderate hair loss Excessive hair loss

< 15 Count 30 30 7 67

% within ferritin 44.8% 44.8% 10.4% 100.0%

[15-40] Count 106 117 20 243

% within ferritin 43.6% 48.1% 8.2% 100.0%

[40-70] Count 175 142 21 338

% within ferritin 51.8% 42.0% 6.2% 100.0%

≥ 70 Count 330 332 41 703

% within ferritin 46.9% 47.2% 5.8% 100.0%

Total Count 641 621 89 1351

% within ferritin 47.4% 46.0% 6.6% 100.0%

Table 4 Impact of iron store levels on hemoglobin level in non-menopausal women (n = 3759)

Ferritin (µg /L) Hemoglobin

< 120 g/L ≥120 g/L Total

< 15 number 173 708 881

% 19.6% 80.4% 100.0%

[15-40] number 43 1226 1269

% 3.4% 96.6% 100.0%

[40-70] number 23 914 937

% 2.5% 97.5% 100.0%

≥ 70 number 7 665 672

% 1.0% 99.0% 100.0%

Total number 246 3513 3759

% 6.5% 93.5% 100.0%


This study, carried out for the first time on a very large cohort of women, provides strong arguments in favor of an association between depleted iron stores and hair loss, particularly excessive hair loss in women before menopause. It is likely that women classified in the present study under “excessive hair loss” were mainly women with androgenetic alopecia [17], however considering their large number, women with CTE [3] might also be included. Since serum ferritin measurement has been reported to be the most sensitive assay for estimating the iron status in an adult population [24], we used this assay to verify a possible link between iron status and hair loss.

Our results fully agreed with previous reports [5, 6, 8, 9] and provide further evidence that the iron status has to be taken into consideration when studying hair loss in women [5] and contrasts with some previous studies where no link between iron deficiency and hair loss was detected. This discrepancy could be explained by differences in the design of the studies. None of the previous studies was performed on an important sample of the general population nor did they take into consideration parameters such as age and haemoglobin concentration in post-menopausal women, and also neglecting the adjustment of the results with the use of contraceptives or intra-uterine devices in non-menopausal women. It is known that menstruating women using intra-uterine devices have significantly lower serum ferritin levels than those without contraception, or using oral contraception [21]. A potential weakness of our study, based on the way the data on hair loss were collected, was compensated by the successful logistic regression model, establishing a link between serum ferritin level and excessive hair loss in non-menopausal women.

According to these results, a decrease in ferritin levels might be considered as a potential risk factor for excessive hair loss. For example, a decrease in 30 units of serum ferritin level in non-menopausal women presenting an initial serum ferritin concentration of 70 µg/L (reference mean value of serum ferritin) would lead to a 28% increase in the odds of excessive hair loss.

Our results support the “threshold hypothesis” [17], which states that decreased iron stores lower the threshold for developing different types of alopecia. Nevertheless, additional studies are required to better understand the biological significance of the critical iron status level of 40 µg/L in the etiology of hair loss.

In hair follicles, iron is implicated as a metabolic factor. Iron is also a main constituent for hemoglobin, and iron depletion leads to anemia. The present study indicates that anemia appears for a ferritin threshold much lower than for hair loss. Consequently in clinical practice, an excessive hair loss supports the need to check serum ferritin levels. The optimum serum ferritin levels to reach for effectiveness on hair loss are higher than those usually recommended for treatment of anemia.


We would like to thank Mrs M. Cartron for her help, Mrs A. Bielicki for her technical assistance, Pr A.M. Roussel (Joseph-Fourier University), Drs P. Preziosi (U557 Inserm), B.A. Bernard and C. Bouillon for critical comments of the manuscript.

Disclosure: The authors attest that they have no conflicts of interest to disclose.


1 Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001; 144: 297-304.

2 Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol 1998; 18: 1073-7.

3 Rushton DH, Norris MJ, Dover R, Busuttil N. Causes of hair loss and the developments in hair rejunevation. Int J cosm Sci 2002; 24: 17-23.

4 Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002; 27: 396-404.

5 Rushton DH. Management of hair loss in women. Dermatol Clin 1993; 11: 47-53.

6 Rushton DH, Ramsay ID, James KC, Norris MJ, Gilkes JJH. Biochemical and trichological characterization of diffuse alopecia in women. Br J Dermatol 1990; 123: 187-97.

7 Futterweit MD, Dunaif A, Yeh H-C, et al. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. J Am Acad Dermatol 1988; 19: 831-6.

8 Roberts JL. Examining the etiology of telogen effluvium in pre-and postmenaupausal women: a chart review study. Tokyo, Japan: Proceeding, Tri-continental hair research Meeting, 2001; (Poster 157).

9 Haycox C. The incidence of depleted iron stores in North american females presenting with hair loss. Tokyo, Japan: Proceedings, Tri-Continental hair research Meeting, 2001; (Poster 159).

10 Milman N, Kirchhoff M. Iron stores in 1359, 30-to 60-year old Danish women: evaluation by serum ferritin and hemoglobin. Ann Hematol 1992; 64: 22-7.

11 Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf) 1992; 36: 421-7.

12 Aydingöz IE, Ferhanoglu B, Guney O. Does tissue iron status have a role in female alopecia? J Eur Acad Dermatol Venereol 1999; 13: 65-7.

13 Auerbach R. Low iron levels. Arch Dermatol 1968; 98: 681.

14 Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002; 147: 982-4.

15 Chamberlain AJ, Dawber RPR. Significance of iron status in hair loss in women. Br J Dermatol 2003; 149: 428.

16 Rushton DH, Dover R, Norris MJ. Is there really no clear association between low serum feritin and chronic diffuse telogen hair loss? Br J Dermatol 2003; 148: 1282-4.

17 Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003; 121: 985-8.

18 Hercberg S, Preziosi P, Briançon S, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU. VI. MAX study-design, methods, and participant characteristics. Control Clin Trials 1998; 19: 336-51.

19 Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, Roussel AM, Favier A, Briançon S. The SU.VI.MAX study: a randomized, placebo controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164: 2335-42.

20 Lebart L, Morineau A, Piron M. In: Statistique exploratoire multidimensionnelle. Paris: Dunod, 1995: 93-176.

21 Galan P, Yoon HC, Preziosi P, et al. Determining factors in the iron status of adult women in the Suvimax women. Eur J Clin Nutr 1998; 52: 383-8.

22 Westfall PH, Tobias RD, Rom D, et al. In: Multiple comparisons and multiple tests using the SAS system. Cary, NC: SAS Institute Inc, 1999: 73-6.

23 Stokes ME, Davis CS, Koch GG. In: Categorical data analysis using the SAS system. Cary, NC: SAS Institute Inc, 2000: 211-70.

24 Hercberg S, Galan P. Nutritional anaemias. In: Flemming AF, ed. Clinical Haematology_International Practice and Research. Bailllière, London: Tindall, 1992: 145-68.

Bilimsel yayın 3

Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups

resented in part at the Fifth International Congress for Hair Research in Vancouver, BC on June 26, 2007.

Elise A. Olsen, MD

Katherine B. Reed, MD

Patrick B. Cacchio, BS

Leslie Caudill, MD


The literature suggests that iron deficiency (ID) may play a role in female pattern hair loss (FPHL) or in chronic telogen effluvium (CTE).


We sought to determine if ID is more common in women with FPHL and/or CTE than in control subjects without hair loss.


This was a controlled study of 381 Caucasian women aged 18 years or older with FPHL or CTE seen in the Duke University Hair Disorders Clinic, Durham, NC, and 76 Caucasian women aged 18 years or older from the university environs who had no history or physical findings of hair loss (control subjects). All participants had to have at least a serum ferritin and hemoglobin reading and history of menopausal status.


When ferritin less than or equal to 15 μg/L was used as the definition, ID occurred in 12.4%, 12.1%, and 29.8% of premenopausal women with FPHL (n = 170), CTE (n = 58), and control subjects (n = 47), respectively, and in 1.7%, 10.5%, and 6.9% of postmenopausal women with FPHL (n = 115), CTE (n = 38), and control subjects (n = 29), respectively. When ferritin less than or equal to 40 μg/L was used as the definition, ID occurred in 58.8%, 63.8%, and 72.3% of premenopausal women with FPHL, CTE, and control subjects, respectively, and in 26.1%, 36.8%, and 20.7% of postmenopausal women with FPHL, CTE, and control subjects, respectively. There was no statistically significant increase in the incidence of ID in premenopausal or postmenopausal women with FPHL or CTE versus control subjects.


The effect of correction of ID on hair loss is unknown.


ID is common in women but not increased in patients with FPHL or CTE compared with control subjects.

Key words: chronic telogen effluvium, female pattern hair loss, ferritin, iron deficiency, iron deficiency anemia

Abbreviations used: CTE, chronic telogen effluvium, DUHDC, Duke University Hair Disorders Clinic, ESR, erythrocyte sedimentation rate,FPHL, female pattern hair loss, ID, iron deficiency, IDA, iron deficiency anemia.

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir

Menopecia © 2018